ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
MWN-AI** Summary
ImmuCell Corporation, an animal health biologics company focused on improving calf productivity and health, has announced significant strategic changes to its Board of Directors. Effective April 15, 2026, Dr. Gilles Guillemette and Dr. Anthony DiMarco will join the board, which will now comprise seven members, including six independent directors and the CEO, Olivier te Boekhorst. This realignment aims to bolster ImmuCell's innovation strategy and enhance corporate governance.
Dr. Guillemette brings over 30 years of executive experience in animal health, with leadership roles at notable companies like Elanco and Bayer. He will chair the newly formed Strategy and Technology Committee, contributing his expertise in strategy and mergers and acquisitions, along with a veterinary background essential to developing clinically relevant innovations. Meanwhile, Dr. DiMarco offers four decades of scientific leadership in human and animal health. His previous tenure at IDEXX highlights his proficiency in new product development and manufacturing processes. He will serve on several committees, including Compensation and Nominations, and contribute to the Strategy and Technology Committee.
Both appointments aim to drive innovation particularly around ImmuCell's flagship product, First Defense®, which offers immediate immunity to neonatal calves using colostrum-derived antibodies. Te Boekhorst emphasized the timely nature of these additions, signifying a concerted effort to leverage expertise in advancing product offerings and operational efficiencies.
As part of these changes, the company also plans to acknowledge the contributions of outgoing board members, including Bryan Gathagan and Michael Brigham, who will step down effective the same date, reflecting ImmuCell's commitment to an independent governance structure. This move sets the stage for enhanced strategic decision-making as ImmuCell continues to evolve and compete in the animal health sector.
MWN-AI** Analysis
ImmuCell Corporation (Nasdaq: ICCC) has recently made significant strides in enhancing its corporate governance and innovation strategy by appointing Dr. Gilles Guillemette and Dr. Anthony DiMarco to its Board of Directors while transitioning to a more streamlined, independent 7-person board. This shift, coupled with the establishment of a Strategy and Technology Committee, positions ImmuCell to strengthen its market presence and accelerate growth, particularly in its key product line, First Defense®.
The addition of Dr. Guillemette, with his extensive experience in animal health therapeutics and executive roles at notable companies like Elanco and Bayer, signals a strategic move towards enhancing ImmuCell's innovation pipeline and operational efficiencies. His leadership in business development and regulated operations will be invaluable as the company seeks to expand its product offerings and improve overall yield and capacity.
Conversely, Dr. DiMarco's robust background in R&D and global manufacturing, especially during his tenure at IDEXX, adds a critical layer of scientific expertise that can drive product development processes. His focus on improving biological manufacturing and developing new animal health products aligns seamlessly with ImmuCell's mission to enhance calf health through innovative solutions.
Analysts should view these appointments as a positive signal for ImmuCell’s future. The commitment to a smaller, independent board could enhance decision-making efficiency and corporate governance, which are vital for attracting long-term investors. Given the rising global demand for effective animal health solutions, ImmuCell's renewed focus on innovation and strategic growth is likely to enhance shareholder value.
Investors may consider monitoring ImmuCell closely as its new board members begin to implement their strategic vision, particularly any advancements regarding First Defense® and potential market expansion initiatives. In conclusion, ImmuCell's evolving strategy positions it favorably within the animal health sector, offering promising prospects for growth and innovation.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve calf health and productivity, announced that Dr. Gilles Guillemette and Dr. Anthony DiMarco have been appointed to its Board of Directors, effective April 15, 2026. The Company also announced it is moving to a 7-person Board of Directors with six Independent Directors and the CEO, and that it will create a Strategy and Technology Committee of the Board of Directors.
Dr. Guillemette has more than 30 years of executive experience in animal health therapeutics. He has held executive positions at Elanco, Bayer, Henry Schein, Chewy, and Trupanion, where he had significant P&L responsibilities, led strategy, business development and finance functions, and managed regulated therapeutic operations. Dr. Guillemette is currently an Operating Partner at Archimed and earned his Doctor of Veterinary Medicine in Nantes, France. He will Chair the new Strategy and Technology Committee and serve on the Audit Committee.
Dr. DiMarco brings four decades of scientific leadership in human and animal health biologics companies. For 21 years, he was Vice President of R&D and Global Manufacturing at IDEXX where he developed new products and implemented productivity improvements. Previously, Dr. DiMarco spent 10 years in scientific roles at Abbott Laboratories. Dr. DiMarco serves as Chair of Educate Maine and received his Ph.D. in Microbiology from the University of Illinois. He will serve on the Compensation, Nominations, and Strategy & Technology Committees.
Dr. DiMarco said, “My first introduction was in helping ImmuCell develop a manufacturing yield improvement plan and I look forward to working with the team to consider opportunities to further develop hyperimmune colostrum technology and expand the First Defense® line.” Mr. Guillemette added, “This is an exciting time to join the ImmuCell Board as the company develops and executes new innovation strategies to accelerate the growth of First Defense®.”
“Dr. Guillemette strengthens our board with expertise in animal health strategy and M&A, complemented by a veterinary background that will help us develop an innovation strategy based on clinical relevance,” commented Olivier te Boekhorst, President and Chief Executive Officer of ImmuCell. “Dr. DiMarco brings experience improving biological manufacturing processes and a track record of developing successful new animal health products. Joined by Gloria Basse and Kathy Turner, they will serve on our new Strategy and Technology Committee that will support management with strategic and technical expertise as we pursue opportunities to improve our yield, expand our capacity, and generate innovation-driven growth of First Defense®. We are also pleased to advance our corporate governance by moving to an independent board.”
The Company is moving to a 7-person Board of Directors with six Independent Directors and the CEO and gratefully acknowledges the many valuable contributions and dedicated service of Bryan Gathagan and non-independent members Michael Brigham and Bobbi Brockmann, who will retire from the Board effective April 15, 2026, and Timothy Fiori who will retire from the Board after the 2026 Annual Meeting. Ms. Brockmann and Mr. Fiori will continue their executive roles at the Company.
Effective April 15, 2026, the independent members of the Board of Directors of ImmuCell will be Dr. David Tomsche DVM (Chair), Ms. Gloria Basse, Dr. Anthony DiMarco Ph.D., Dr. Gilles Guillemette DVM, Ms. Kathy Turner, and Mr. Paul Wainman.
About ImmuCell
ImmuCell Corporation (Nasdaq: ICCC) is an animal health biologics company serving the dairy and beef industries with practical, science-based solutions that improve the survivability, health, and long-term performance of dairy and beef calves. The Company’s primary product line, First Defense®, provides Immediate Immunity™ through colostrum-derived, orally delivered antibodies against the principal viral and bacterial causes of scours, one of the most prevalent and deadly diseases in neonatal calves worldwide. The Annual Meeting of Stockholders of ImmuCell Corporation will be held remotely via a live audio webcast as well as by telephone conference call on Thursday, June 11, 2026 at 9:30 AM ET. Press releases and other information about the Company, including an updated Investor Presentation that provides an overview of the Company’s business, are available at http://www.immucell.com/investors.
| Contacts: | Olivier te Boekhorst, President and CEO | |
| Timothy C. Fiori, Chief Financial Officer | ||
| ImmuCell Corporation | ||
| investor.relations@immucell.com | ||
| Joe Diaz, Robert Blum and Joe Dorame | ||
| Lytham Partners, LLC | ||
| iccc@lythampartners.com |
FAQ**
How do the recent appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board of ImmuCell Corporation ICCC enhance its strategic focus on animal health and innovation?
What specific objectives does the newly formed Strategy and Technology Committee of ImmuCell Corporation ICCC aim to achieve in terms of product development and operational efficiency?
With the transition to a 7-person Board at ImmuCell Corporation ICCC, how will the company's governance structure impact its long-term growth and decision-making processes?
What are the anticipated benefits for ImmuCell Corporation ICCC in expanding its First Defense® product line, particularly in relation to improving calf health and productivity?
**MWN-AI FAQ is based on asking OpenAI questions about ImmuCell Corporation (NASDAQ: ICCC).
NASDAQ: ICCC
ICCC Trading
-6.22% G/L:
$9.50 Last:
4,443 Volume:
$9.77 Open:
